<DOC>
	<DOCNO>NCT01329718</DOCNO>
	<brief_summary>Epigenomics identify methylated gene region specific colorectal cancer ( CRC ) . Through Epigenomics ' marker discovery validation process Septin 9 identify particularly robust methylation marker detection CRC . Epigenomics currently develop blood base CRC screen test base Septin 9 perform large prospective clinical trial show clinical utility population average risk CRC . Parallel trial activity need evaluate , optimize , develop pre-analytical analytical workflow well molecular assay make possible use Septin 9 methylation clinical routine .</brief_summary>
	<brief_title>Specimens Septin 9 Performance</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>50 year age old time blood draw Histologically confirm strong clinical suspicion adenocarcinoma colon rectum CRC define invasive adenocarcinoma Previous personal history colorectal cancer Any cancer specific treatment ( e.g . polypectomy , chemotherapy , radiation , surgery ) prior blood draw , include neoadjuvant treatment Known infection HIV , HBV HCV Subject concurrently receive intravenous fluid time specimen collection</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Stability Septin 9 biomarker</keyword>
	<keyword>Epi Pro Colon Test</keyword>
	<keyword>CRC</keyword>
</DOC>